Literature DB >> 979078

Coagulation studies and platelet function after somatostatin infusion.

H Rasche, S Raptis, R Scheck, E F Pfeiffer.   

Abstract

The effect of short- and long-term somatostatin (GIF) administration on haemostatic function in man was investigated. The dosage programme applied in this study was 250 mug GIF as a bolus injection and 250 mug GIF/h by way of infusion. In five healthy volunteers a short-term (3h) treatment resulted in a statistically significant drop of platelet count and impairment of platelet aggregation at the end of infusion. However, these changes were within the physiologically normal range and disappeared after two hours on all subjects. Other parameters such as bleeding time, thromboplastin and partial thromboplastin time, fibrinogen, fibrin/fibrinogen split products, plasma factor XIII, ethanol gelation test were not affected. In two patients with gastric haemorrhage and persistent amylasaemia a 67 or 120-h treatment induced no remarkable haemostatic defect. By contrast, peptic ulcer bleeding in one patient stopped 60 min after starting the GIF infusion. These studies indicated that somatostatin administration in man at the dosage programme used neither results in clinical evidence indicating bleeding tendency nor does it influence laboratory parameters in an apparent way.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 979078     DOI: 10.1007/BF01468948

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  39 in total

1.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

2.  Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics.

Authors:  J E Gerich; M Lorenzi; V Schneider; C W Kwan; J H Karam; R Guillemin; P H Forsham
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

3.  Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man.

Authors:  J E Gerich; M Lorenzi; V Schneider; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

4.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

5.  Factor XIII consumption as an indicator of thrombin generation.

Authors:  D C Triantaphyllopoulos
Journal:  J Lab Clin Med       Date:  1974-07

6.  Antidiabetic action of somatostatin--assessed by the artificial pancreas.

Authors:  C Meissner; C Thum; W Beischer; G Winkler; K E Schröder; E F Pfeiffer
Journal:  Diabetes       Date:  1975-11       Impact factor: 9.461

7.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

8.  [Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)].

Authors:  W Creutzfeldt; P G Lankisch; U R Fölsch
Journal:  Dtsch Med Wochenschr       Date:  1975-05-16       Impact factor: 0.628

9.  The effect of somatostatin on platelet aggregation.

Authors:  T M Chiang; W C Duckworth; E H Beachey; A H Kang
Journal:  Endocrinology       Date:  1975-09       Impact factor: 4.736

10.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.